The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw an decrease this past trading week. NBI went down 1.37 percent over the last five trading days and traded at 3,472.32 points. The Index is up 25.23 percent year-to-date.
Last week the US Food and Drug Administration made headlines by approving the second gene therapy treatment for cancer ever. Yescarta by Kite Pharma, which was acquired by Gilead Sciences (NASDAQ:GILD), is a cell therapy treatment for adults with certain types of large B-cell lymphoma. “We believe this is only the beginning for CAR-T therapies,” Arie Belldegrun, M.D., FACS, founder of Kite, said in a statement, as reported by Genetic Engineering and Biotechnology News. “The FDA approval of Yescarta is a landmark for patients with relapsed or refractory large B-cell lymphoma.”
Here are last week’s top gainers on the NASDAQ:
- Aevi Genomic Medicine (NASDAQ:GNMX)
- Viking Therapeutics (NASDAQ:VKTX)
- Lifevantage (NASDAQ:LFVN)
- Trillium Therapeutics (NASDAQ:TRIL)
- MEI Pharma (NASDAQ:MEIP)
Aevi Genomic Medicine
Aevi Genomic Medicine is a genomic company working on advancing therapies for patients with pediatric onset life-altering diseases. Last week the company announced it completed a $28 million private offer for 22.2 million shares of its common stock with warrants to purchase approximately 4.0 million additional shares.
Aevi Genomic Medicine gained 37.30 percent last week and closed the week at $1.73 per share.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. On October 4 the company shared its top line data from a 25-week proof of concept study for VK0214 in an in vivo model of x-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics gained 31.58 percent last week and closed the week at $3 per share.
LifeVantage is a science-based network marketing company, focused on helping people achieve their health goals. The company held its annual European Leadership Academy at the Claus Event Center on October 8, 2017.
Lifevantage gained 31.22 percent last week and closed the week at $6.43 per share.
Trillium is an immuno-oncology company working on the discovery and development of novel and innovative cancer therapies. Last week the company announced its new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 were presented at the EORTC CLTF meeting.
Trillium Therapeutics gained 18.18 percent last week and closed the week at $7.15 per share.
MEI Pharma is an oncology company focused on the clinical development of novel therapies for cancer. The company hasn’t put out a press release since Sept. 19, when the announced president and chief executive officer Dr. Daniel P. Gold would present at the then upcoming Cantor Fitzgerald Global Healthcare Conference.
MEI Pharma gained 16.52 percent last week and closed the week at $2.68 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.